Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWYS-49 is an inhibitor of platelet aggregation.1 It inhibits ADP-, collagen-, or epinephrine-induced platelet aggregation in isolated human platelets (IC50s = 730, 92, and 3.4 µM, respectively). YS-49 also inhibits platelet aggregation and production of thromboxane A2 (TXA2) induced by arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) in isolated rat platelets (IC50s = 3.3 and 32.8 µM, respectively).2 It reduces LPS-induced contractions in isolated endothelium-denuded rat aortic strips in a concentration-dependent manner.3 YS-49 (50 mg/kg) decreases thrombus weight in a rat model of arterio-venous shunt thrombosis.1 It increases survival in a mouse model of septicemia induced by LPS when administered at doses of 10 and 20 mg/kg.3
WARNING This product is not for human or veterinary use.
1. Antithrombotic effects of YS-
2. Effects of higenamine and its 1-
3. Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS 49, in rat vascular smooth muscle and RAW 264.7 macrophages. Br. J. Pharmacol. 128(2), 357-364 (1999).